Journal Mobile Options

Vol. 35, No. 5-6, 1999

Issue release date: May–June 1999

Strategies for the Chemoprevention of Prostate Cancer

Symposium, Brussels, October 1998

See also ISBN 978-3-8055-6866-1 for more details
Select / Unselect all
Contents
I

Vol. 35, 1999

Eur Urol 1999;35:I–IV (DOI:10.1159/000019903)
Free Access
Strategies for the Chemoprevention of Prostate Cancer
337

Contents Vol. 35, No. 5–6, 1999

Eur Urol 1999;35:337–340 (DOI:10.1159/000019904)
Free Access
341

Introduction

Eur Urol 1999;35:341 (DOI:10.1159/000019905)
Free Access
 
342

Chemoprevention of Prostate Cancer: Concepts and Strategies

Kelloff G.J. · Lieberman R. · Steele V.E. · Boone C.W. · Lubet R.A. · Kopelovitch L. · Malone W.A. · Crowell J.A. · Sigman C.C.
Eur Urol 1999;35:342–350 (DOI:10.1159/000019906)
Genetic and Environmental Factors in Prostate Cancer Genesis
351

Molecular Biology of Progression of Prostate Cancer

Nupponen N. · Visakorpi T.
Eur Urol 1999;35:351–354 (DOI:10.1159/000019907)
Further Section
354

Congress Calendar

Eur Urol 1999;35:354 (DOI:10.1159/000019908)
Free Access
Genetic and Environmental Factors in Prostate Cancer Genesis
355

Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility

Ross R.K. · Coetzee G.A. · Pearce C.L. · Reichardt J.K.V. · Bretsky P. · Kolonel L.N. · Henderson B.E. · Lander E. · Altshuler D. · Daley G.
Eur Urol 1999;35:355–361 (DOI:10.1159/000019909)
362

Genetic and Environmental Factors in Prostate Cancer Genesis:Identifying High-Risk Cohorts

Ekman P.
Eur Urol 1999;35:362–369 (DOI:10.1159/000019910)
370

Epidemiology of Prostate Cancer Chemoprevention

Boyle P. · Severi G.
Eur Urol 1999;35:370–376 (DOI:10.1159/000019911)
377

Diet and Its Preventive Role in Prostatic Disease

Denis L. · Morton M.S. · Griffiths K.
Eur Urol 1999;35:377–387 (DOI:10.1159/000019912)
388

Dietary Fat and Prostate Cancer Progression and Survival

Fradet Y. · Meyer F. · Bairati I. · Shadmani R. · Moore L.
Eur Urol 1999;35:388–391 (DOI:10.1159/000019913)
Molecular Targets for Chemoprevention of Prostate Cancer
392

Vitamin D and Prostate Cancer Risk

Peehl D.M.
Eur Urol 1999;35:392–394 (DOI:10.1159/000019914)
395

Lipoxygenase Inhibition in Prostate Cancer

Myers C.E. · Ghosh J.
Eur Urol 1999;35:395–398 (DOI:10.1159/000019915)
399

Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy

Moul J.W.
Eur Urol 1999;35:399–407 (DOI:10.1159/000019916)
408

Changes in Gene Expression and Targets for Therapy

Bussemakers M.J.G.
Eur Urol 1999;35:408–412 (DOI:10.1159/000019917)
413

Mechanism of Androgen Receptor Activation and Possible Implications for Chemoprevention Trials

Klocker H. · Culig Z. · Eder I.E. · Nessler-Menardi C. · Hobisch A. · Putz T. · Bartsch G. · Peterziel H. · Cato A.C.B.
Eur Urol 1999;35:413–419 (DOI:10.1159/000019918)
420

New Agents for Chemoprevention of Prostate Cancer

Sporn M.B.
Eur Urol 1999;35:420–423 (DOI:10.1159/000019873)
424

Retinoids in Chemoprevention

Whelan P.
Eur Urol 1999;35:424–428 (DOI:10.1159/000019874)
429

Evaluation of Biomarker Modulation by Fenretinide in Prostate Cancer Patients

Urban D. · Myers R. · Manne U. · Weiss H. · Mohler J. · Perkins D. · Markiewicz M. · Lieberman R. · Kelloff G. · Marshall M. · Grizzle W.
Eur Urol 1999;35:429–438 (DOI:10.1159/000019875)
439

Factors Controlling the Expression of 5α-Reductase in Human Prostate: A Possible New Approach for the Treatment of Prostate Cancer

Habib F.K. · Ross M. · Bayne C.W.
Eur Urol 1999;35:439–442 (DOI:10.1159/000019876)
443

Certain Aspects of Molecular Endocrinology That Relate to the Influence of Dietary Factors on the Pathogenesis of Prostate Cancer

Griffiths K. · Morton M.S. · Denis L.
Eur Urol 1999;35:443–455 (DOI:10.1159/000019877)
Preclinical Models for Drug Discovery
456

High-Grade Prostatic Intraepithelial Neoplasia in Dogs

Waters D.J.
Eur Urol 1999;35:456–458 (DOI:10.1159/000019878)
459

Use of Animal Models in Defining Efficacy of Chemoprevention Agents against Prostate Cancer

Bosland M.C.
Eur Urol 1999;35:459–463 (DOI:10.1159/000019879)
464

Chemoprevention of Hormone-Dependent Prostate Cancer in the Wistar-Unilever Rat

McCormick D.L. · Rao K.V.N.
Eur Urol 1999;35:464–467 (DOI:10.1159/000019880)
Surrogate Endpoint Biomarkers for Clinical Trials of Prostate Cancer Chemoprevention
468

Subtle Morphological and Molecular Changes in Normal-Looking Epithelium in Prostates with Prostatic Intraepithelial Neoplasia or Cancer

Montironi R. · Hamilton P.W. · Scarpelli M. · Thompson D. · Bartels P.H.
Eur Urol 1999;35:468–473 (DOI:10.1159/000019881)
474

Prostatic Intraepithelial Neoplasia: A Marker for High-Risk Groups and a Potential Target for Chemoprevention

Sakr W.A.
Eur Urol 1999;35:474–478 (DOI:10.1159/000019882)
479

Genetic and Chromosomal Alterations in Prostatic Intraepithelial Neoplasia and Carcinoma Detected by Fluorescence in situ Hybridization

Qian J. · Jenkins R.B. · Bostwick D.G.
Eur Urol 1999;35:479–483 (DOI:10.1159/000019883)
484

Tissue Architecture Analysis in Prostate Cancer and Its Precursors: An Innovative Approach to Computerized Histometry

Bartels P.H. · Montironi R. · Duval da Silva V. · Hamilton P.W. · Thompson D. · Vaught L. · Bartels H.G.
Eur Urol 1999;35:484–491 (DOI:10.1159/000019884)
492

Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention

Bostwick D.G. · Neumann R. · Qian J. · Cheng L.
Eur Urol 1999;35:492–495 (DOI:10.1159/000019885)
496

Evolution of Isolated High-Grade Prostate Intraepithelial Neoplasia in a Mediterranean Patient Population

Algaba F.
Eur Urol 1999;35:496–497 (DOI:10.1159/000019886)
498

Clinical Evolution of Prostatic Intraepithelial Neoplasia

Zlotta A.R. · Schulman C.C.
Eur Urol 1999;35:498–503 (DOI:10.1159/000019887)
504

PIN I–III: When Should We Interfere?

Newling D.
Eur Urol 1999;35:504–507 (DOI:10.1159/000019888)
508

Prostatic Intraepithelial Neoplasia and Endocrine Manipulation

van der Kwast T.H. · Labrie F. · Têtu B.
Eur Urol 1999;35:508–510 (DOI:10.1159/000019889)
511

The Utility of Prostate-Specific Antigen as a Surrogate Marker for Identification of High-Risk Cohorts and Assessing Response in Chemoprevention Trials

Crawford E.D.
Eur Urol 1999;35:511–514 (DOI:10.1159/000019890)
Clinical Trial Designs for Chemoprevention of Prostate Cancer
515

Practical Aspects of Clinical Trials on Chemoprevention of Prostate Cancer

van der Meijden A.P.M.
Eur Urol 1999;35:515–518 (DOI:10.1159/000019891)
519

Statistical Considerations of Chemoprevention Clinical Trials in Prostate Cancer

Sylvester R. · Collette L.
Eur Urol 1999;35:519–522 (DOI:10.1159/000019892)
523

Prostate Cancer Screening in Tyrol, Austria: Experience and Results

Horninger W. · Reissigl A. · Rogatsch H. · Volgger H. · Studen M. · Klocker H. · Bartsch G.
Eur Urol 1999;35:523–538 (DOI:10.1159/000019893)
539

The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update

Schröder F.H. · Kranse R. · Rietbergen J. · Hoedemaeker R. · Kirkels W.
Eur Urol 1999;35:539–543 (DOI:10.1159/000019894)
544

Prostate Cancer Prevention Trial (PCPT) Update

Thompson, Jr. I.M. · Feigl P.
Eur Urol 1999;35:544–547 (DOI:10.1159/000019895)
Index
548

Author Index Vol. 35, No. 5–6, 1999

Eur Urol 1999;35:548 (DOI:10.1159/000019896)
Free Access
549

Subject Index Vol. 35, No. 5–6, 1999

Eur Urol 1999;35:549 (DOI:10.1159/000019897)
Free Access
Further Section
550

Forthcoming Papers

Eur Urol 1999;35:550 (DOI:10.1159/000019898)
Free Access
551

Acknowledgement to the Reviewers

Eur Urol 1999;35:551 (DOI:10.1159/000019899)
Free Access
Index
552

Author Index Vol. 35, 1999

Eur Urol 1999;35:552–553 (DOI:10.1159/000019900)
Free Access
554

Subject Index Vol. 35, 1999

Eur Urol 1999;35:554–556 (DOI:10.1159/000019901)
Free Access
2.4 Curriculum in Urology: Infections and Stones
557

Prostatitis and Urethritis

Eur Urol 1999;35/5–6 (Curric Urol 2.4:1–10) (DOI:10.1159/000019902)